InterventionsHuman trial

Mazdutide Improves Markers of Insulin Sensitivity in Adults with Obesity without Type 2 Diabetes

ADA Scientific Sessions 2026 Abstract

The paper

Melissa K. Thomas, Ann Marie K. Weideman, Tamer Coskun,

Axel Haupt, Olímpia Ferreira Galvão de Araújo,

Kieren J. Mather

Bad Homburg

ADA Scientific Sessions 2026 Abstract · 5 Jun 2026

Presented at ADA Scientific Sessions 2026 · Poster 1693-P

doi.org/10.2337/db26-1693-p

A triple-target drug cut body weight by up to 19.7% in a trial
Cell Metabolism · 8 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
The New England Journal of Medicine · 4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
Lancet · 4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
Lancet · 4 Oct 2026